

 Early Warning System

EIB-20220218

GBS (IEU LS)



## Quick Facts

Countries	Germany
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2022-12-09
Borrower	GERMAN BIONIC SYSTEMS GMBH
Sectors	Industry and Trade
Investment Type(s)	Loan
Loan Amount (USD)	\$ 15.82 million
Project Cost (USD)	\$ 32.70 million



---

## Project Description

According to the disclosure page, this project supports the research and development of exoskeletons and related services, as well as capital expenditures and costs related to market access.

The project will enhance the promoter's technology edge and capabilities supporting the development and deployment of new technologies and innovative, high-value-added products and services, addressing the prevention of musculoskeletal disorders and lower back pain, amongst others.



---

## Investment Description

- European Investment Bank (EIB)



---

## Private Actors Description

As stated by Bloomberg, GBS German Bionic Systems GmbH develops and manufactures exoskeleton systems. The Company offers a wearable human-robotic exoskeleton which supports users in different industries while manual handling of goods and tools. GBS German Bionic Systems serves customers in Germany and Japan.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	German Bionic Systems GmbH	Client	Industry and Trade



---

## Contact Information

*No project contact information was published at the time of the disclosure.*

### Client - German Bionic Systems:

Address: August-Wessels-Strasse 23, 86156 Augsburg, Germany

Email: [info@germanbionic.com](mailto:info@germanbionic.com)

Phone: +49 (0) 821 907 497 80

Website: <https://germanbionic.com/en/>

## ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

## ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: [complaints@eib.org](mailto:complaints@eib.org), by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: [http://www.eib.org/attachments/strategies/complaints\\_mechanism\\_policy\\_en.pdf](http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf)

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



---

## Media

- [Germany: InvestEU - EIB invests in high-tech workplace safety with €15 million for exoskeleton manuf](#)





---

## Other Related Projects

- EIB-20220302 LIFE SCIENCES (INVESTEU VD) PL